Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism
Besides their well-established roles in dietary lipid absorption and cholesterol homeostasis, bile acids (BA) also act as metabolically active signaling molecules. The flux of reabsorbed BA undergoing enterohepatic circulation, arriving in the liver with the co-absorbed nutrients (e.g. glucose, lipids), provides a signal that coordinates hepatic triglyceride (TG), glucose and energy homeostasis. As signaling molecules with systemic endocrine functions, BA can activate protein kinases A and C as well as mitogen-activated protein kinase pathways. Additionally, they are ligands for a G-protein-coupled BA receptor (TGR5/Gpbar-1) and activate nuclear receptors such as farnesoid X receptor (FXR; NR1H4). FXR and its downstream targets play a key role in the control of hepatic de novo lipogenesis, very-low-density lipoprotein-TG export and plasma TG turnover. BA-activated FXR and signal transduction pathways are also involved in the regulation of hepatic gluconeogenesis, glycogen synthesis and insulin sensitivity. Via TGR5, BA are able to stimulate glucagon-like peptide-1 secretion in the small intestine and energy expenditure in brown adipose tissue and skeletal muscle. Dysregulation of BA transport and impaired BA receptor signaling may contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Thus, BA transport and BA-controlled nuclear receptors and signaling pathways are promising drug targets for treatment of NAFLD. As such, FXR and/or TGR5 ligands have shown promising results in animal models of NAFLD and clinical pilot studies. Despite being a poor FXR and TGR5 ligand, ursodeoxycholic acid (UDCA) improves hepatic ER stress and insulin sensitivity. Notably, <i>nor</i>UDCA, a side chain-shortened homologue of UDCA, improves fatty liver and atherosclerosis in Western diet-fed ApoE<sup>–/–</sup> mice. Collectively, these findings suggest that BA and targeting their receptor/signaling pathways may represent a promising approach to treat NAFLD and closely linked disorders such as obesity, diabetes, dyslipidemia and arteriosclerosis.
Топ-30
Журналы
|
1
2
3
4
5
6
7
|
|
|
Hepatology
7 публикаций, 2.59%
|
|
|
PLoS ONE
6 публикаций, 2.22%
|
|
|
Scientific Reports
5 публикаций, 1.85%
|
|
|
Nutrients
4 публикации, 1.48%
|
|
|
Journal of Lipid Research
4 публикации, 1.48%
|
|
|
Frontiers in Pharmacology
3 публикации, 1.11%
|
|
|
Digestive Diseases
3 публикации, 1.11%
|
|
|
World Journal of Gastroenterology
3 публикации, 1.11%
|
|
|
Journal of Steroid Biochemistry and Molecular Biology
3 публикации, 1.11%
|
|
|
F1000Research
3 публикации, 1.11%
|
|
|
Drug Metabolism and Disposition
2 публикации, 0.74%
|
|
|
Journal of Endocrinology
2 публикации, 0.74%
|
|
|
American Journal of Gastroenterology
2 публикации, 0.74%
|
|
|
Experimental Biology and Medicine
2 публикации, 0.74%
|
|
|
Journal of Clinical Medicine
2 публикации, 0.74%
|
|
|
Frontiers in Microbiology
2 публикации, 0.74%
|
|
|
Frontiers in Nutrition
2 публикации, 0.74%
|
|
|
Frontiers in Endocrinology
2 публикации, 0.74%
|
|
|
Laboratory Investigation
2 публикации, 0.74%
|
|
|
Journal of Physiology and Biochemistry
2 публикации, 0.74%
|
|
|
Journal of Gastroenterology
2 публикации, 0.74%
|
|
|
Nature Reviews Gastroenterology and Hepatology
2 публикации, 0.74%
|
|
|
Journal of Hepatology
2 публикации, 0.74%
|
|
|
Gastroenterology
2 публикации, 0.74%
|
|
|
Biochimica et Biophysica Acta - Molecular Basis of Disease
2 публикации, 0.74%
|
|
|
Molecular and Cellular Endocrinology
2 публикации, 0.74%
|
|
|
Food and Chemical Toxicology
2 публикации, 0.74%
|
|
|
Biochemical and Biophysical Research Communications
2 публикации, 0.74%
|
|
|
Clinical Nutrition
2 публикации, 0.74%
|
|
|
1
2
3
4
5
6
7
|
Издатели
|
10
20
30
40
50
60
70
80
90
|
|
|
Elsevier
82 публикации, 30.37%
|
|
|
Springer Nature
38 публикаций, 14.07%
|
|
|
Wiley
21 публикация, 7.78%
|
|
|
MDPI
16 публикаций, 5.93%
|
|
|
Frontiers Media S.A.
14 публикаций, 5.19%
|
|
|
Taylor & Francis
11 публикаций, 4.07%
|
|
|
Public Library of Science (PLoS)
7 публикаций, 2.59%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
5 публикаций, 1.85%
|
|
|
American Society for Biochemistry and Molecular Biology
5 публикаций, 1.85%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
4 публикации, 1.48%
|
|
|
Baishideng Publishing Group
4 публикации, 1.48%
|
|
|
SAGE
4 публикации, 1.48%
|
|
|
Hindawi Limited
4 публикации, 1.48%
|
|
|
Georg Thieme Verlag KG
4 публикации, 1.48%
|
|
|
S. Karger AG
3 публикации, 1.11%
|
|
|
American Chemical Society (ACS)
3 публикации, 1.11%
|
|
|
Royal Society of Chemistry (RSC)
3 публикации, 1.11%
|
|
|
Oxford University Press
3 публикации, 1.11%
|
|
|
American Physiological Society
3 публикации, 1.11%
|
|
|
F1000 Research
3 публикации, 1.11%
|
|
|
Bioscientifica
2 публикации, 0.74%
|
|
|
The Endocrine Society
2 публикации, 0.74%
|
|
|
LLC Global Media Technology
2 публикации, 0.74%
|
|
|
American Diabetes Association
2 публикации, 0.74%
|
|
|
Alfmed LLC
2 публикации, 0.74%
|
|
|
AME Publishing Company
2 публикации, 0.74%
|
|
|
Bentham Science Publishers Ltd.
1 публикация, 0.37%
|
|
|
The Company of Biologists
1 публикация, 0.37%
|
|
|
Institute of Physiology of the Czech Academy of Sciences
1 публикация, 0.37%
|
|
|
10
20
30
40
50
60
70
80
90
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.